Women's Health

Bremelanotide NDA Submitted to FDA for Hypoactive Sexual Desire Disorder

By March 26, 2018

Bremelanotide is used as needed prior to anticipated sexual activity.

Progestin-Only Contraceptives and Depression: Is There a Link?

By February 28, 2018

Study quality was graded according to the United States Preventive Services Task Force and the Cochrane Risk of Bias Tools.

Verzenio Gains Expanded Breast Cancer Indication

By February 27, 2018

The approval of Verzenio as initial therapy in combination with an aromatase inhibitor is based on the efficacy and safety demonstrated in the pivotal MONARCH 3 clinical trial.

Drug-Free Supplements Launched for Menopause Symptom Relief

By December 15, 2017

The drug-free supplements also contain varying levels of flax, vitamin B2, vitamin B6, D-biotin, and vitamin D3.

Elagolix NDA Submitted for Treating Endometriosis-Associated Pain

By September 06, 2017

Elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist, was evaluated in two Phase 3 clinical studies in about 1,700 women with moderate-to-severe endometriosis-associated pain.

Liletta Approved to Prevent Pregnancy for up to Four Years

By August 07, 2017

The FDA's approval of the supplemental New Drug Application (sNDA) was based on efficacy and safety data from the ongoing Phase 3 ACCESS IUS trial.

Efficacy of Treatments Compared for Female Pattern Hair Loss

By June 07, 2016

The safety and efficacy of topical minoxidil for the treatment of female pattern hair loss was supported by moderate to low quality evidence in a recent Cochrane systematic review.